Barry Paul

ORCID: 0000-0003-2702-8225
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Chronic Myeloid Leukemia Treatments
  • Polyamine Metabolism and Applications
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Amino Acid Enzymes and Metabolism
  • Immunotherapy and Immune Responses
  • Peptidase Inhibition and Analysis
  • Research on Leishmaniasis Studies
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • HIV/AIDS drug development and treatment
  • Cancer therapeutics and mechanisms
  • Epigenetics and DNA Methylation
  • Cancer Mechanisms and Therapy
  • Ubiquitin and proteasome pathways
  • Metabolism and Genetic Disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Advanced Breast Cancer Therapies
  • Digitalization, Law, and Regulation
  • Trauma, Hemostasis, Coagulopathy, Resuscitation
  • Adipokines, Inflammation, and Metabolic Diseases
  • Pericarditis and Cardiac Tamponade
  • Cardiovascular Function and Risk Factors
  • Biosimilars and Bioanalytical Methods

Levine Cancer Institute
2019-2024

Wake Forest University
2024

Northern Indiana Cancer Research Consortium
2016

St. John Hospital & Medical Center
2016

Indian Institute of Toxicology Research
2013

Fortis Escorts Heart Institute
2004

Magrolimab is a monoclonal antibody that blocks CD47, 'do not eat me' signal overexpressed on tumor cells. CD47 in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown blockade induces macrophage activation, resulting elimination of cells, and there synergy between magrolimab certain anticancer therapies. These findings suggest magrolimab-based combinations may therapeutic benefit MM. This phase II study investigates combination with commonly used...

10.2217/fon-2022-0975 article EN cc-by-nc-nd Future Oncology 2023-01-01

Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through blockage XPO1, which increases retention tumor suppressor proteins (TSPs), including p53, thereby limiting translation oncogenes, triggering cell cycle arrest and death malignant cells. Multiple Myeloma (MM) patients with del17p are deficient in TP53 have particularly poor prognosis. Given unique mechanism action, we investigated whether...

10.3390/life14030384 article EN cc-by Life 2024-03-14

Elephant numbers have drastically declined over the past century with illegal killings, habitat fragmentation and human-elephant-conflict representing greatest threats. Information on estimates of abundance demographics are important to understand long-term implications these Mark-resighting studies can provide valuable insights but depend individual identification numerous elephants within populations across both Africa Asia. Most photographic elephant still reliant human memory manual...

10.69649/pachyderm.v61i.65 article FR Pachyderm 2020-10-08

The present study determines the fat depot-specific expression of leptin and TNF-α its association with biochemical parameters in postmenopausal women. A total 108 women were recruited prospectively; 54 metabolic syndrome (cases) without (controls). Leptin mRNA visceral adipose tissue (VAT) subcutaneous (SAT) done by Real Time-RT PCR. In cases, mean (±SD) serum estrogen was significantly lower (41.33±24.90 vs. 23.95±14.45, p<0.001) while (12.85±4.51 10.34±3.89, p=0.002) (13.81±7.13...

10.1055/s-0033-1358706 article EN Hormone and Metabolic Research 2013-12-02
Coming Soon ...